Collaborative Research and Development Agreement Sample Contracts
Exhibit 10.10 FIFTH AMENDMENT TO COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT DATED 1ST SEPTEMBER, 1995 This Amendment (the "Fifth Amendment") dated 1 December 2001, is entered into by and between: E. I. du Pont de Nemours and Company, a...Collaborative Research and Development Agreement • March 29th, 2002 • Genencor International Inc • In vitro & in vivo diagnostic substances
The University of Tokyo, RIKEN, Nichi-Iko and Daiichi Sankyo Reach Basic Agreement on Collaborative R&D on Nafamostat Inhalation Formulation for Treatment of Novel Corona Virus Infection (COVID-19)Collaborative Research and Development Agreement • November 28th, 2024
In the first stage of infection by the causative virus of COVID-19, SARS-CoV-2, the outer envelope of the virus fuses with the host cell surface membrane. Prof. Junichiro Inoue, Institute of Medical Science, The University of Tokyo (at the time of the study, currently Senior Professor at the University of Tokyo) and others discovered that by preventing this fusion, Nafamostat could efficiently inhibit the viral entry process. Nafamostat is an injectable that has been prescribed mainly as a treatment for acute pancreatitis and disseminated intravascular coagulation for many years in Japan and adequate safety-related clinical data has been accumulated.
RECITALSCollaborative Research and Development Agreement • September 15th, 2000 • Rigel Pharmaceuticals Inc • Services-commercial physical & biological research • California
iNHiBIKASE THERAPEUTICS FIRST AMENDMENT TO COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTCollaborative Research and Development Agreement • July 23rd, 2020 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT TO THE COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (“Agreement”) is entered into with an effective date as of the 5th day of October 2012 (the “Amendment Effective Date”) by and among, on the one hand, Inhibikase Therapeutics, Inc., a Delaware corporation, with offices located at 3350 Riverwood Parkway, Suite 1927, Atlanta, Georgia (the “Company”) and, on the other hand, Sphaera Pharma Pte. Ltd., a company incorporated under the laws of Singapore with its registered office at 8 Temasek Boulevard, #22-03 Suntec Tower 3, Singapore 038988 (“Sphaera Singapore”) and Sphaera Phanna Pvt. Ltd., with its registered office at E-375, First Floor, Greater Kailash-II, New Delhi-110048, INDIA (“Sphaera India”)(together with Sphaera Singapore, hereinafter referred to as “Sphaera Pharma”). (Company and Sphaera Pharma shall be referred to individually as a “Party” and collectively as the “Parties.”) Except as otherwise provided in this Agreement, capitalized terms and phrases
InhiBIkase Therapeutics COLLABORATIVE RESEARCH AND DEvELOPMENT AGREEMENTCollaborative Research and Development Agreement • July 23rd, 2020 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
THIS COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (“Agreement”) is entered into with an effective date as of this 29th day of February 2012, by and among, on the one hand. Inhibikase Therapeutics, Inc., a Delaware corporation, with offices located at 3350 Riverwood Parkway. Suite 1927, Atlanta. Georgia (the “Company”) and. on the other hand. Sphaera Pharma Pte, Ltd., a company incorporated under the laws of Singapore with its registered office at 8 Temasek Boulevard. #22-03 Suntec Tower 3, Singapore 038988 (“Sphaera Singapore”) and Sphaera Pharma Pvt. Ltd., Plot No. 32, Sector 5, IMT Manesar Haryana 122051, India (“Sphaera India”) (together with Sphaera Singapore, hereinafter referred to as “Sphaera Pharma”). (Company and Sphaera Pharma shall be referred to individually as a “Party” and collectively as the “Parties.”)
COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTCollaborative Research and Development Agreement • May 9th, 2014 • Agenus Inc • Biological products, (no disgnostic substances) • England and Wales
THIS COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (this “Agreement”) is made the 23rd. day of May, 2011 (“EFFECTIVE DATE”) by and between the LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, a Swiss not-for-profit corporation, with its registered office at Stadelhoferstrasse 22, 8001, Zurich, Switzerland, and having an office at 666 Third Avenue, New York, NY 10017, United States of America (“LICR”) and 4-ANTIBODY AG (“4AB”), incorporated in Switzerland at Schwarzwaldallee 215, CH-4002 Basel, Switzerland.
COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTCollaborative Research and Development Agreement • March 9th, 2021 • Longeveron Inc. • Pharmaceutical preparations • Florida
This COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (the “Agreement”) is entered into as of the 3rd day of March, 2021 (the “Effective Date”) by and between Longeveron, Inc, a corporation organized under the laws of the State of Delaware and having offices at 1951 NW 7th Avenue, Miami, Florida 33136 (“Longeveron”), and University of Miami, a not-for-profit corporation having an office at 1320 S. Dixie Highway, Gables One Tower #650, Locator Code 2960, Coral Gables, FL 33146 (the “Institution”). Each of Longeveron and Institution are sometimes referred to herein as a “Party” or, jointly, as the “Parties.”
Exhibit 10.22 [CERTAIN MATERIAL (INDICATED BY A [*CON*]) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION] COLLABORATIVE...Collaborative Research and Development Agreement • March 28th, 2002 • Mitokor • Pharmaceutical preparations • New York
October 16, 2015Collaborative Research and Development Agreement • September 1st, 2022
Pressure BioSciences and Florida International University Enter Into Formal Agreement to Develop an Improved Rape Kit Test Method Based on PBI's Patented PCT Platform
COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT BY AND BETWEEN ENUMERAL BIOMEDICAL HOLDINGS, INC. and THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER January 11, 2016Collaborative Research and Development Agreement • March 30th, 2016 • Enumeral Biomedical Holdings, Inc. • Pharmaceutical preparations • Texas
This COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (this “Agreement”) is entered into as of January 11, 2016 (the “Effective Date”) by and between Enumeral Biomedical Holdings, Inc., a Delaware corporation with offices at 200 Cambridge Park Drive, Cambridge, MA 02140 (with its subsidiaries, “Enumeral”), and The University of Texas M. D. Anderson Cancer Center, a member institution of The University of Texas System (“System”) and an agency of the State of Texas, with offices at 1515 Holcombe Blvd., Houston, Texas 77030 (“MDACC”). Each of MDACC and Enumeral is sometimes referred to individually herein as a “Party” and collectively as the “Parties”.
The University of Tokyo, RIKEN, Nichi-Iko and Daiichi Sankyo Reach Basic Agreement on Collaborative R&D on Nafamostat Inhalation Formulation for Treatment of Novel Corona Virus Infection (COVID-19)Collaborative Research and Development Agreement • June 5th, 2020
In the first stage of infection by the causative virus of COVID-19, SARS-CoV-2, the outer envelope of the virus fuses with the host cell surface membrane. Prof. Junichiro Inoue, Institute of Medical Science, The University of Tokyo (at the time of the study, currently Senior Professor at the University of Tokyo) and others discovered that by preventing this fusion, Nafamostat could efficiently inhibit the viral entry process. Nafamostat is an injectable that has been prescribed mainly as a treatment for acute pancreatitis and disseminated intravascular coagulation for many years in Japan and adequate safety-related clinical data has been accumulated.
COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT BY AND BETWEEN ARQULE, INC. and BERYLLIUM DISCOVERY CORP. May 4, 2015Collaborative Research and Development Agreement • August 5th, 2015 • Arqule Inc • Pharmaceutical preparations • Massachusetts
This COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (this “Agreement”) is entered into as of May 4, 2015 (the “Effective Date”) by and between ArQule, Inc., a Delaware corporation with offices at One Wall Street, Burlington, MA 01803 (“ArQule”), and Beryllium Discovery Corp., a Washington corporation with offices at Preston Court, Bedford, MA 01730 (“Beryllium”). Each of Beryllium and ArQule is sometimes referred to individually herein as a “Party” and collectively as the “Parties”.
NSERC COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTCollaborative Research and Development Agreement • October 3rd, 2016 • Ontario
WHEREAS, uOttawa is the largest bilingual (English‐French) university in the world; and WHEREAS, uOttawa ranks among the top 10 research universities in Canada; and
TERMS AND CONDITIONS RELATED TO A COLLABORATIVE RESEARCH AND DEVELOPMENT PROJECTCollaborative Research and Development Agreement • October 31st, 2023
Exhibit 99.1 COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT This Agreement, dated and effective as of this 11th day of November, 2004 (Effective Date), is made by and between INFOTONICS TECHNOLOGY CENTER INC., a not-for-profit corporation having an...Collaborative Research and Development Agreement • November 15th, 2004 • Mediscience Technology Corp • Surgical & medical instruments & apparatus • New York
BIRDF FUNDED COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTCollaborative Research and Development Agreement • March 3rd, 2025 • NLS Pharmaceutics Ltd. • Pharmaceutical preparations • Delaware
THIS BIRDF FUNDED COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (“Agreement”) dated as of April 29, 2023 (the “Effective Date”), is entered into by and between Kadimastem Ltd., a public company formed and registered under the laws of the State of Israel (“Kadimastem”) with a principal address located at Pinchas Sapir 7, Weizmann Science Park, Nes-Ziona, Israel, and iTolerance, Inc., a Delaware corporation with a principal address located at 1951 NW 7th Ave., Suite 300 Miami, FL 33136 USA (“iTolerance”). Each of Kadimastem and iTolerance is referred to as a “Party”, and collectively as “Parties.”
Ma Jun majun@tsinghua.edu.cnCollaborative Research and Development Agreement • September 1st, 2004
As one of the key science and innovation infrastructure of the country, Tsinghua aimed at building itself into a comprehensive, research-oriented, open world-class university in the year 2011. R&D innovation, personnel training and contribution to the society are three critical functions of university. Tsinghua is trying harder to promote R&D level to committee to China’s social and economicic development. Therefore collaborative R&D between Tsinghua University and multinational companies will not only promote Tsinghua’s leading edge R&D but also as a tool to serve the sociality to further enhance China’s global competitiveness.
COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTCollaborative Research and Development Agreement • December 10th, 2020
Société d’Exploitation de Produits pour l’Industrie Chimique SEPPIC, a French company (Société Anonyme) registered at the Trade and Companies’ Register of Paris under No. 552 016 487, having its registered office at 75, Quai d’Orsay, 75007 Paris, France, and which is represented by Mrs. Juliette BEN AROUS, acting as Formulation and Vaccine Technologies Unit Director of SEPPIC,
COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTCollaborative Research and Development Agreement • October 2nd, 2019 • AVRA Medical Robotics, Inc. • Surgical & medical instruments & apparatus • Florida
THIS COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (the “Agreement”) is entered into as of this 10th day of September (the “Effective Date”), by and between INFINITE MIND LLC (“IM”), a Florida limited liability company having a place of business at 3259 Progress Drive, Suite 107, Orlando, Florida 32826 and AVRA MEDICAL ROBOTICS, INC. (“AVRA”), a Florida corporation having a place of business at 3259 Progress Drive, Suite 114, Orlando, Florida 32826
COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTCollaborative Research and Development Agreement • July 8th, 2021
Please see the attached document prepared pursuant to Article 16.1 of COLLABORATIVE RESEARCH AGREEMENT (20XX) for determined amounts of EXPERIMENT EXPENDITURE.
COMVITA NEW ZEALAND LIMITED DERMA SCIENCES, INCCollaborative Research and Development Agreement • March 1st, 2010 • Derma Sciences, Inc. • Surgical & medical instruments & apparatus
COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTCollaborative Research and Development Agreement • January 10th, 2007 • Arizona
This Collaborative Research and Development Agreement, hereinafter referred to as the “Agreement,” consists of this Cover Page, an attached Agreement, and various Appendices referenced in the Agreement. This Cover Page serves to identify the Parties to this Agreement:
Collaborative Research And Development AgreementCollaborative Research and Development Agreement • February 4th, 2021
Intend to be a collaborative research development agreement that relates to be in the hhs patent prosecutor and amounts to delay the information of pbs
Agreement on Collaborative Research and Development in scope of the “Reliable Time-Sensitive Networks in Distributed Cyber-Physical Systems for Real-Time Control Industry 4.0 Applications” projectCollaborative Research and Development Agreement • January 26th, 2018
The 4 above listed contracting parties (hereinafter referred to as “Parties”) agreed to work on a joint research and development project called “Reliable Time-Sensitive Networks in Distributed Cyber-Physical Systems for Real-Time Control Industry 4.0 Applications” (hereinafter referred to as “Project”) according to terms specified in this agreement (hereinafter referred to as “Agreement”).